Physician profile
Michael E Jones
NPI 1083611636
$1,904.67
in general payments reported to CMS, 2019-2025
24 companies · $393 in 2025
The $393 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $218 · 2020: $130 · 2021: $338 · 2022: $258 · 2023: $259 · 2024: $310 · 2025: $393.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $962.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $961.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $652.84 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $497.50 | 2019-2025 | Tremfya |
| Madrigal Pharmaceuticals | $134.24 | 2025 | Rezdiffra |
| Redhill Biopharma INC. | $95.65 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $93.46 | 2019-2025 | Xifaxan |
| Daiichi Sankyo INC. | $59.63 | 2019-2023 | Injectafer |
| Gilead Sciences, INC. | $58.92 | 2019-2023 | |
| Nestle Healthcare Nutrition INC. | $54.09 | 2021-2022 | |
| Celgene Corporation | $38.71 | 2021-2023 | Zeposia |
| Neuraxis, INC. | $37.00 | 2025 | |
| Pfizer INC. | $30.91 | 2019-2023 | |
| Lilly USA, LLC | $29.56 | 2023 | |
| Phathom Pharmaceuticals, INC. | $24.87 | 2024 | Voquezna |
| Intercept Pharmaceuticals, INC. | $21.12 | 2019 | |
| Ethicon US, LLC | $16.56 | 2025 | Linx Reflux Management System |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $16.46 | 2020 | |
| Merck Sharp & Dohme LLC | $15.45 | 2021 | |
| Janssen Biotech, INC. | $14.09 | 2023 | Stelara |
| Ferring Pharmaceuticals INC. | $13.61 | 2025 | Rebyota |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.